Andrew Tsai
Andrew Tsai is a financial analyst at Jefferies, specializing in the biotechnology sector. He is noted for his optimistic outlook on the potential success of azetukalner, predicting that it could become a leading epilepsy treatment and generate over a billion dollars in annual sales.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| Canada | 1 | 8.00 | 0.16% | +0% | 38,005,238 | 62,406 | $1,700,000 | 2,791$ |
| Totals | 1 | 38,005,238 | 62,406 | $1,700,000 | 2,791$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Canada:
Jefferies analyst Andrew Tsai said in a recent note that the drug has already produced one of the most compelling pivotal datasets in focal epilepsy.
8